Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

quinine (Rx)Brand and Other Names:Qualaquin

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 324mg
more...

Malaria

Uncomplicated (P. falciparum)

  • 648 mg PO q8hr x 7 days

Chloroquine -Resistant (P. falciparum)

  • 648 mg PO q8hr x 3-7 days with concomitant tetracycline, doxycycline, or clindamycin

Chloroquine-Resistant (P. vivax)

  • 648 mg PO q8hr x 3-7 days with concomitant doxycycline (or tetracycline) and PO primaquine

Babesiosis

648 mg PO q8hr x 7 days, with concomitant PO or IV clindamycin

Dosage Modifications

Severe, chronic renal impairment: 648 mg PO once, then 324 mg PO q12hr

Hepatic impairment

  • Mild or moderate (Child-Pugh A or B): No dosage adjustment required; monitor closely
  • Severe (Child-Pugh C): Do not administer

Dosage Forms & Strengths

capsule

  • 324mg
more...

Malaria

Uncomplicated (P. falciparum)

  • 30 mg/kg/day PO divided TID x 3–7 days  
  • Should not exceed the usual adult PO dosage.

Chloroquine-Resistant (P. falciparum)

  • 30 mg/kg/day PO divided TID x3-7 days, with concomitant doxycycline, tetracycline or clindamycin
  • Should not exceed the usual adult PO dosage.

Chloroquine-Resistant (P. vivax)

  • 30 mg/kg/day PO TID x 3–7 days, with concomitant doxycyline & PO primaquine
  • Should not exceed the usual adult PO dosage.

Babesiosis (Off-label)

25 mg/kg/day PO divided TID x7 days, with concomitant oral clindamycin 

Next

Interactions

Interaction Checker

quinine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            <1%

            Flushing of the skin

            Anginal symptoms

            Fever

            Rash

            Pruritus

            Hypoglycemia

            Epigastric pain

            Hemolysis in G6PD deficiency

            Thrombocytopenia

            Hepatitis

            Nightblindness

            Diplopia

            Optic atrophy

            Impaired hearing

            Hypersensitivity reaction

            Frequency Not Defined

            Severe headache

            Nausea

            Vomiting

            Diarrhea

            Blurred vision

            Tinnituscinchonism (risk of cinchonism is directly related to dose and duration of therapy)

            Previous
            Next

            Warnings

            Black Box Warnings

            Limited or no benefit for treatment/prevention of nocturnal leg cramps

            May cause serious and life-threatening hematologic reactions, including thrombocytopenia and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP)

            Chronic renal impairment associated with the development of TTP has been reported

            Contraindications

            Hypersensitivity

            G6PD deficiency

            Optic neuritis, tinnitus, history of quinine-associated blackwater fever and thrombocytopenic purpura

            Pregnancy

            Cautions

            Reduce parenteral dose by half if >48 hr parenteral treatment required; monitor EKG, BP, glucose with parenteral treatment

            FDA warns against unapproved use for leg cramps because of unpredictable serious and life-threatening hematologic reactions including thrombocytopenia and hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP)

            QT prolongation

            • Concentration-dependent prolongation of the PR and QRS interval observed
            • At particular risk are patients with underlying structural heart disease and preexisting conduction system abnormalities, elderly patients with sick sinus syndrome, patients with atrial fibrillation with slow ventricular response, patients with myocardial ischemia or patients receiving drugs known to prolong the PR interval (eg, verapamil) or QRS interval (eg, flecainide or quinidine)
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: X (first trimester)

            Lactation: enters breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Absorption: readily, mainly from upper small intestine

            Protein Bound: 70-95%

            Metabolism: primarily hepatic

            Half-life elimination: children: 6-12 hr; adults: 8-14 hr

            Peak Plasma Time: 1-3 hr

            Excretion: feces & saliva; urine (<5% as unchanged drug)

            Mechanism of Action

            Unknown; may disrupt Plasmodium DNA transcription/replication

            Previous
            Next

            Administration

            IV Administration

            Was administered by slow IV infusion as the dihydrochloride; however, a parenteral dosage form of the drug no longer is available in the US

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.